PNPLA2 and fatty liver disease: Further, overexpressing ATGL specifically in the liver of obese mice did decrease liver steatosis, but it only mildly enhanced liver insulin sensitivity [58], suggesting that ATGL might be a pharmacological therapeutic target for NAFLD but not type 2 diabetes.